Lymphoid malignancies: Another face to the Janus kinases

Blood Reviews

Volumn 27, Issue 2, 2013, Pages 63-70

  Scott, Linda M ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

Author keywords

Acute lymphoblastic leukemia; JAK inhibitors; JAK2

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR LIKE FACTOR 2; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; INTERLEUKIN 7 RECEPTOR ALPHA; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE INHIBITOR; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PLACEBO; PROTEIN KINASE TYK2; PU H71; RUXOLITINIB; THYMIC STROMAL LYMPHOPOIETIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CANCER RESISTANCE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DOWN SYNDROME; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GAIN OF FUNCTION MUTATION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; JAK STAT SIGNALING PATHWAY; JAK1 GENE; JAK2 GENE; LEUKEMIA REMISSION; LEUKEMOGENESIS; LYMPHOMA; MYELOID METAPLASIA; MYELOPOIESIS; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPLENOMEGALY; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84875277794     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2012.12.004     Document Type: Article

References (100)

1. Pui C.H., Robison L.L., Look A.T. Acute lymphoblastic leukaemia. Lancet 2008, 371:1030-1043.
2. Nguyen K., Devidas M., Cheng S.C., et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. Leukemia 2008, 22:2142-2150.
3. de Klein A., van Kessel A.G., Grosveld G., et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982, 300:765-767.
4. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
5. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
6. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
7. Schultz K.R., Bowman W.P., Aledo A., et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009, 27:5175-5181.
8. Thomis D.C., Gurniak C.B., Tivol E., Sharpe A.H., Berg L.J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995, 270:794-797.
9. Nosaka T., van Deursen J.M., Tripp R.A., et al. Defective lymphoid development in mice lacking Jak3. Science 1995, 270:800-802.
10. Rodig S.J., Meraz M.A., White J.M., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998, 93:373-383.
11. Karaghiosoff M., Neubauer H., Lassnig C., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 2000, 13:549-560.
12. Shimoda K., Kato K., Aoki K., et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000, 13:561-571.
13. Parganas E., Wang D., Stravopodis D., et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998, 93:385-395.
14. Neubauer H., Cumano A., Muller M., Wu H., Huffstadt U., Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998, 93:397-409.
15. Krempler A., Qi Y., Triplett A.A., Zhu J., Rui H., Wagner K.U. Generation of a conditional knockout allele for the Janus kinase 2 (Jak2) gene in mice. Genesis 2004, 40:52-57.
16. Saharinen P., Takaluoma K., Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000, 20:3387-3395.
17. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277:47954-47963.
18. Ungureanu D., Wu J., Pekkala T., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat Struct Mol Biol 2011, 18:971-976.
19. Bandaranayake R.M., Ungureanu D., Shan Y., Shaw D.E., Silvennoinen O., Hubbard S.R. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat Struct Mol Biol 2012, 19:754-759.
20. Hanratty W.P., Dearolf C.R. The Drosophila Tumorous-lethal hematopoietic oncogene is a dominant mutation in the hopscotch locus. Mol Gen Genet 1993, 238:33-37.
21. Harrison D.A., Binari R., Nahreini T.S., Gilman M., Perrimon N. Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects. EMBO J 1995, 14:2857-2865.
22. Luo H., Rose P., Barber D., et al. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol Cell Biol 1997, 17:1562-1571.
23. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
24. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434:1144-1148.
25. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005, 352:1779-1790.
26. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
27. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356:459-468.
28. Scott L.M. JAK2 exon 12 mutations: a comprehensive review. Am J Hematol 2011, 86:668-676.
29. Scott L.M., Beer P.A., Bench A.J., Erber W.N., Green A.R. Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 2007, 139:511-512.
30. Prchal J.F., Axelrad A.A. Bone marrow responses in polycythemia vera. N Engl J Med 1974, 290:1382.
31. Sanz A., Ungureanu D., Pekkala T., et al. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS One 2011, 6:e18522.
32. Tiedt R., Hao-Shen H., Sobas M.A., et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood 2008, 111:3931-3940.
33. Li S., Hao-Shen H., Tiedt R., Skoda R.C. Transgenic mice expressing a JAK2 exon 12 mutation display isolated erythrocytosis closely resembling the human JAK2 exon 12 polycythemia. 15th Congress of the European Hematology Association. Barcelona, Spain 2010.
34. Li J., Spensberger D., Ahn J.S., et al. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood 2010, 116:1528-1538.
35. Larsen T.S., Christensen J.H., Hasselbalch H.C., Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007, 136:745-751.
36. Levine R.L., Loriaux M., Huntly B.J., et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005, 106:3377-3379.
37. Scott L.M., Campbell P.J., Baxter E.J., et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005, 106:2920-2921.
38. Kratz C.P., Boll S., Kontny U., Schrappe M., Niemeyer C.M., Stanulla M. Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 2006, 20:381-383.
39. Reiter A., Walz C., Watmore A., et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65:2662-2667.
40. Lacronique V., Boureux A., Valle V.D., et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997, 278:1309-1312.
41. Peeters P., Raynaud S.D., Cools J., et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 1997, 90:2535-2540.
42. Poitras J.L., Dal Cin P., Aster J.C., Deangelo D.J., Morton C.C. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 2008, 47:884-889.
43. Mullighan C.G., Morin R., Zhang J., et al. Next generation transcriptomic resequencing identifies novel genetic alterations in high-risk (HR) childhood acute lymphoblastic leukemia (ALL): a report from the Children's Oncology Group (COG) HR ALL TARGET project. Blood 2009, 114:293. [abstract 704].
44. Nebral K., Denk D., Attarbaschi A., et al. Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia. Leukemia 2009, 23:134-143.
45. Carron C., Cormier F., Janin A., et al. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000, 95:3891-3899.
46. Van Roosbroeck K., Cox L., Tousseyn T., et al. JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma. Blood 2011, 117:4056-4064.
47. Meydan N., Grunberger T., Dadi H., et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379:645-648.
48. Hasle H., Clemmensen I.H., Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000, 355:165-169.
49. Malinge S., Izraeli S., Crispino J.D. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009, 113:2619-2628.
50. Mundschau G., Gurbuxani S., Gamis A.S., Greene M.E., Arceci R.J., Crispino J.D. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003, 101:4298-4300.
51. Dordelmann M., Schrappe M., Reiter A., et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia 1998, 12:645-651.
52. Zeller B., Gustafsson G., Forestier E., et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol 2005, 128:797-804.
53. Ross J.A., Spector L.G., Robison L.L., Olshan A.F. Epidemiology of leukemia in children with Down syndrome. Pediatr Blood Cancer 2005, 44:8-12.
54. Pui C.H., Raimondi S.C., Borowitz M.J., et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol 1993, 11:1361-1367.
55. Whitlock J.A., Sather H.N., Gaynon P., et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2005, 106:4043-4049.
56. Malinge S., Ben-Abdelali R., Settegrana C., et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007, 109:2202-2204.
57. Bercovich D., Ganmore I., Scott L.M., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372:1484-1492.
58. Kearney L., Gonzalez De Castro D., Yeung J., et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009, 113:646-648.
59. Gaikwad A., Rye C.L., Devidas M., et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol 2009, 144:930-932.
60. Giordanetto F., Kroemer R.T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng 2002, 15:727-737.
61. Mullighan C.G., Zhang J., Harvey R.C., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009, 106:9414-9418.
62. Staerk J., Kallin A., Demoulin J.B., Vainchenker W., Constantinescu S.N. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J Biol Chem 2005, 280:41893-41899.
63. Flex E., Petrangeli V., Stella L., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008, 205:751-758.
64. Hornakova T., Staerk J., Royer Y., et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. J Biol Chem 2009, 284:6773-6781.
65. Hornakova T., Chiaretti S., Lemaire M.M., et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010, 115:3287-3295.
66. Lu X., Levine R., Tong W., et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A 2005, 102:18962-18967.
67. Lu X., Huang L.J., Lodish H.F. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J Biol Chem 2008, 283:5258-5266.
68. Levin S.D., Koelling R.M., Friend S.L., et al. Thymic stromal lymphopoietin: a cytokine that promotes the development of IgM+ B cells in vitro and signals via a novel mechanism. J Immunol 1999, 162:677-683.
69. Sims J.E., Williams D.E., Morrissey P.J., et al. Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J Exp Med 2000, 192:671-680.
70. Friend S.L., Hosier S., Nelson A., Foxworthe D., Williams D.E., Farr A. A thymic stromal cell line supports in vitro development of surface IgM+ B cells and produces a novel growth factor affecting B and T lineage cells. Exp Hematol 1994, 22:321-328.
71. Akasaka T., Balasas T., Russell L.J., et al. Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2007, 109:3451-3461.
72. Russell L.J., Akasaka T., Majid A., et al. t(6;14)(p22;q32): a new recurrent IGH@ translocation involving ID4 in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood 2008, 111:387-391.
73. Mullighan C.G., Collins-Underwood J.R., Phillips L.A., et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 2009, 41:1243-1246.
74. Russell L.J., Capasso M., Vater I., et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 2009, 114:2688-2698.
75. Ensor H.M., Schwab C., Russell L.J., et al. Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial. Blood 2011, 117:2129-2136.
76. Harvey R.C., Mullighan C.G., Chen I.M., et al. Rearrangement of CRLF2 is associated with mutations of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010, 115:5312-5321.
77. Hertzberg L., Vendramini E., Ganmore I., et al. Down Syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2. A report from the iBFM-Study Group. Blood 2010, 115:1006-1017.
78. Chapiro E., Russell L., Lainey E., et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010, 24:642-645.
79. Yoda A., Yoda Y., Chiaretti S., et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2010, 107:252-257.
80. van Bodegom D., Zhong J., Kopp N., et al. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood 2012, 120:2853-2863.
81. Shochat C., Tal N., Bandapalli O.R., et al. Gain-of-function mutations in interleukin-7 receptor alpha (IL7R) in childhood acute lymphoblastic leukemias. J Exp Med 2011, 208:901-908.
82. Zhang J., Ding L., Holmfeldt L., et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
83. Zenatti P.P., Ribeiro D., Li W., et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011, 43:932-939.
84. Lasho T.L., Tefferi A., Hood J.D., Verstovsek S., Gilliland D.G., Pardanani A. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia 2008, 22:1790-1792.
85. Hexner E.O., Serdikoff C., Jan M., et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 2008, 111:5663-5671.
86. Porcu M., Kleppe M., Gianfelici V., et al. Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia. Blood 2012, 119:4476-4479.
87. Cario G., Zimmermann M., Romey R., et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. Blood 2010, 115:5393-5397.
88. Verstovsek S., Mesa R.A., Gotlib J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
89. Harrison C., Kiladjian J.J., Al-Ali H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
90. Tefferi A., Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011, 86:1188-1191.
91. Verstovsek S., Kantarjian H., Mesa R.A., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010, 363:1117-1127.
92. Maude S.L., Tasian S.K., Vincent T., et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 2012, 120:3510-3518.
93. Wernig G., Kharas M.G., Okabe R., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
94. Pardanani A., Gotlib J.R., Jamieson C., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29:789-796.
95. Branford S., Rudzki Z., Walsh S., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002, 99:3472-3475.
96. Deshpande A., Reddy M.M., Schade G.O., et al. Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 2012, 26:708-715.
97. Hornakova T., Springuel L., Devreux J., et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011, 96:845-853.
98. Weigert O., Lane A.A., Bird L., et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med 2012, 209:259-273.
99. Koppikar P., Bhagwat N., Kilpivaara O., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.
100. Marubayashi S., Koppikar P., Taldone T., et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010, 120:3578-3593.